[1]
M. Shoae, M. Khorashadizadeh, A. Derakhshani, M. R. Safarnejad, and H. Safarpour, “An overview of the current status of engineered therapeutic monoclonal antibodies”, Int Pharm Acta, vol. 2, no. 1, pp. 2e9:1–10, Dec. 2019.